Aclaris Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2024
Filed with the SEC on Feb 27, 2025 and accepted by EDGAR at Feb 27, 2025, 16:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2024-01-01 to 2024-12-31 | $18.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2024-01-01 to 2024-12-31 | $2.8m | us-gaap:CostOfRevenue |
| Research and development | 12 months2024-01-01 to 2024-12-31 | $33.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2024-01-01 to 2024-12-31 | −$141.9m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2024-01-01 to 2024-12-31 | −$132.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | −$1.71 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | −$1.71 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2024-01-01 to 2024-12-31 | 77,296,665 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −$20.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | $121.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-12-31 | $24.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $126.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $220.3m | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $31.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $64.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-12-31 | $155.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-25-001819. Last ingested by Listed: Nov 5, 2026, 18:44 ET. Listed shows no prices and gives no investment advice.